IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Lenvatinib (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms IMMUNIB
Most Recent Events
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 23 Mar 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results assessing the efficacy of nivolumab in combination with lenvatinib as first line treatment in patients with advanced hepatocellular carcinoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.